Sunday 18 October 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
39.65
1.82
−4.39%
Follow SPRB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
— | 264.58 | 845.29 | — | — | — | — | — | — |
Altman Z-Score |
— | 36.60 | 181.29 | — | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | (20.34) | (1.71) | — | — | — | — | — | — |
P/Operating CF |
— | (62.84) | (760.83) | — | — | — | — | — | — |
P/B ratio |
— | 45.08 | 111.47 | — | — | — | — | — | — |
Price to Tangible BV |
— | 45.08 | 111.47 | — | — | — | — | — | — |
EV/Sales |
— | 257.05 | 836.07 | — | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
— | (22.56) | (253.50) | — | — | — | — | — | — |
EV/FCF |
— | (22.55) | (253.43) | — | — | — | — | — | — |
Quick Ratio |
4.85 | 2.54 | 3.94 | 6.35 | 10.03 | 16.10 | 0.91 | 1.52 | — |
Current Ratio |
5.17 | 2.90 | 4.18 | 6.72 | 10.36 | 16.43 | 1.08 | 1.76 | — |
Net Debt/EBITDA |
1.34 | 0.66 | 1.77 | 1.57 | 2.00 | 5.20 | (0.04) | 0.41 | — |
Debt/Assets |
0.00% | 3.86% | 3.21% | 5.74% | 4.14% | 2.75% | 94.74% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.06 | 0.04 | 0.07 | 0.05 | 0.03 | (1.57) | 0.00 | — |
Asset Turnover |
0.00 | 0.07 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.86 | 1.06 | 0.69 | 0.90 | 0.85 | 0.93 | 0.96 | 0.87 | — |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | (0.09) | (0.49) | (2.06) | (0.33) | 0.00 | — |
Interest Coverage |
(405.70) | (182.90) | (107.65) | (112.58) | (121.93) | (91.07) | (201.65) | — | — |
| (109.24%) | (100.70%) | (66.10%) | (51.35%) | (32.43%) | (49.73%) | 54.04% | 40.70% | — | |
| (79.34%) | (71.12%) | (50.55%) | (43.54%) | (29.23%) | (35.25%) | (276.50%) | (412.90%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (95.12%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(92.72%) | (183.14%) | (61.66%) | (64.90%) | (50.94%) | (19.61%) | (3,750.14%) | (476.69%) | — |
Average Days of Receivables |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 945.18% | 489.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 298.19% | 125.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 108.90% | 45.81% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
— | 0.02 | 0.01 | — | — | — | — | — | — |
Graham Number |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
— | (4.07%) | (0.56%) | — | — | — | — | — | — |
Free Cash Flow Yield |
— | (4.31%) | (0.39%) | — | — | — | — | — | — |
Revenue per Share |
0.00 | 8.93 | 19.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(43.45) | (101.75) | (64.96) | (133.22) | (115.47) | (345.28) | (1,236.96) | (0.38) | — |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.03) | (0.30) | (0.93) | (0.39) | 0.00 | — |
Free Cash Flow per Share |
(43.45) | (101.75) | (64.98) | (133.24) | (115.77) | (346.21) | (1,237.35) | (0.38) | — |
Cash per Share |
63.76 | 70.46 | 188.09 | 252.72 | 286.35 | 1,971.77 | 384.71 | 0.18 | — |
Shareholders Equity per Share |
55.43 | 52.40 | 149.37 | 218.88 | 358.45 | 1,874.87 | (276.86) | 0.09 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
55.43 | 52.40 | 149.37 | 218.88 | 358.45 | 1,874.87 | (276.86) | 0.09 | — |
Free Cash Flow |
(33.33) | (55.96) | (33.28) | (41.69) | (35.97) | (27.59) | (12.62) | (8.57) | — |
Working Capital |
42.03 | 28.96 | 77.72 | 71.16 | 83.02 | 150.63 | 0.35 | 2.07 | — |
Capital Expenditures |
— | — | (0.01) | (0.01) | (0.09) | (0.07) | 0.00 | — | — |
Net Current Asset Value |
41.61 | 27.82 | 74.75 | 66.45 | 76.78 | 146.94 | (2.86) | 2.07 | — |
EV/EBIT |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
— | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Cash ROIC |
(36.45%) | (80.73%) | (18.89%) | (27.34%) | (17.50%) | (8.87%) | (227.61%) | (138.63%) | — |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 839,500.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
1.12 | 2.31 | 2.38 | 2.12 | 3.23 | 2.75 | 2.09 | 2.09 | — |
Average Assets |
49.12 | 74.58 | 94.80 | 106.07 | 144.68 | 83.79 | 4.73 | 2.39 | — |
Average Common Equity |
35.67 | 52.67 | 72.50 | 89.93 | 130.40 | 59.40 | (24.22) | (24.22) | — |
Columns are period end dates